65
Participants
Start Date
October 3, 2018
Primary Completion Date
December 31, 2021
Study Completion Date
December 31, 2021
Blood test
Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing
Skin biopsies
In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)
Hôpital Claude Huriez, CHU, Lille
Collaborators (1)
GlaxoSmithKline
INDUSTRY
University Hospital, Lille
OTHER